{
  "docId": "019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "docSlug": "5bc6ecf6756c39ce2bfe560c6ffb0fc7",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 31,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Slide 26 of a pitch deck, likely from atai Life Sciences.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e8f5-748b-98ae-3f4a3c3c68f5/26",
  "deckHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "deckJsonHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5.json",
  "deckAnchorHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.82,
        "x": 0.09,
        "y": 0.84
      },
      "kind": "callout",
      "text": "Beta power increase indicates potential for anxiolytic activity, while absence of Alpha power reduction suggests basis for less sedation than with benzodiazepines",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ebf8f98-5c56-44f7-aaf2-b310ad52f55a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Log10 Power vs Frequency (Hz) showing delta, theta, alpha, beta, gamma bands",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5871dacc-e890-48df-9864-ac13e594238f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.38,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Beta Power Increase over time (Hr01-Hr12)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb4e3f7a-604f-4f7e-a769-25c57097e5d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.89,
        "x": 0.02,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Beta power increase is in line with pharmacodynamic efficacy of exogenous neurosteroids and benzodiazepines",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db3a1e42-eb61-4f30-8bc8-48ee851d7917",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "source-note",
      "text": "Sensitivity Analysis: Line plot showing Beta power Δ (mean±SEM) at each hour for placebo and GRX-917 (combined 200mg and 300mg cohorts).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85539129-1f03-46a8-bf2d-bcbd6ce35900",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.55,
        "y": 0.76
      },
      "kind": "source-note",
      "text": "Calculation of Difference Wave: Difference Waves (Δ = post minus pre) were compared between GRX-917 and Placebo at each hour and frequency of interest.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97f7c05d-dd9d-4ab6-8c2e-f29540d0d6f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.89,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 1 Study: GRX-917 Pharmacodynamic Evidence of Target Engagement",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbc5495b-a074-464a-96d8-305024f100d8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "8ece1832-091f-4679-9084-40b9de4af7c3",
      "evidence": "chart/line: Log10 Power vs Frequency (Hz) showing delta, theta, alpha, beta, gamma bands",
      "confidence": 0.7
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "dd2f5c48-2c46-4a14-85fc-02e868854099",
      "evidence": "chart/line: Log10 Power vs Frequency (Hz) showing delta, theta, alpha, beta, gamma bands",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 26,
      "beatId": "635b7e22-38e6-4141-9fdb-80493e955c4a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The presentation outlines the expected milestones and timelines for the drug development programs, providing a clear plan for future progress.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}